Die Suchmaschine für Unternehmensdaten in Europa

EU-Förderung (5.000.000 €): Heavy Ion Therapy Research Integration plus Hor 10.03.2021 EU-Rahmenprogramm für Forschung und Innovation "Horizont"

Auf einen Blick

Text

Heavy Ion Therapy Research Integration plus

The goal of Heavy Ion Therapy Research Integration plus (HITRIplus) is to integrate and propel biophysics and medical research on cancer treatment with heavy ions beams while jointly developing its sophisticated instruments. Cancer is a central health problem for our society. Heavy ion beams irradiate tumours by focussing on the ill tissue while sparing the healthy part around, more effectively than any other irradiation treatment. The wider objective of HITRIplus is to provide radiation oncologists with a cutting-edge tool to treat the fraction of tumours that are not curable with X-rays or protons or have better survival rates or lower recurrences with ions. For this major initiative, HITRIplus has gathered a consortium engaging all relevant stakeholders and for the first time bringing together all four European ion therapy centres with leading EU industries, academia, and research laboratories. They all share the ambition to jointly build a strong pan-European Heavy Ion Therapy Research Community. A strategic partner is the South East European International Institute for Sustainable Technologies, which federates eight countries in South East Europe with the ambition to build a next generation heavy ion Research Infrastructure in the area, to boost research and cooperation in a region trying to rebuild after a troubled past. HITRIplus Transnational Access will integrate and open to external researchers the experimental programme of the five European facilities providing therapeutic ion beams. Its Networks will structure and foster the research on heavy ion therapy, including clinical and pre-clinical research. Joint Research Activities will develop new accelerator and beam delivery technologies to extend the reach of the present generation centres and to define a new European reference design, at lower cost and dimensions, to make cancer ion therapy more accessible and to open new markets to European industry.


Geförderte Unternehmen:

Firmenname Förderungssumme
Association Pour LE Soutien DE L'Institut International DE L'Europe Du SUD-EST Pour Les Technologies Durables 825.440 €
Bevatech GmbH 100.000 €
Centro de Investigaciones Energeticas Medioambientales y Tecnologicas 65.000 €
Commissariat a L Energie Atomique et aux Energies Alternatives 87.000 €
Cosylab Laboratorij ZA Kontrolne Sisteme d.d. 158.563 €
EBG Medaustron GmbH 375.807 €
Fondazione Centro Nazionale Di Adroterapia Oncologica 857.052 €
GSI Helmholtzzentrum FUR Schwerionenforschung GmbH 711.500 €
Heidelberger Ionenstrahl Therapie (HIT) Betriebs Gesellschaft AM Universitatsklinikum Heidelberg mbH 0,00 €
HUN-REN Wigner Fizikai Kutatokozpont 18.000,00 €
Istituto Nazionale Di Fisica Nucleare 184.000 €
Organisation Europeenne Pour LA Recherche Nucleaire 329.500 €
Paul Scherrer Institut 13.000,00 €
Philipps Universitaet Marburg 55.000 €
Rigas Tehniska Universitate 85.000 €
Universita TA Malta 47.260 €
Universitatsklinikum Giessen UND Marburg GmbH 325.850 €
Universitatsklinikum Heidelberg 726.029 €
Uppsala Universitet 36.000 €

Quelle: https://cordis.europa.eu/project/id/101008548

Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.